<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03675685</url>
  </required_header>
  <id_info>
    <org_study_id>EN3835-103</org_study_id>
    <nct_id>NCT03675685</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of a Single Dose of CCH (3.36 mg) in Subjects With EFP</brief_title>
  <official_title>A Phase 1, Open-Label Study to Assess the Safety and Pharmacokinetics of a Single Dose of CCH (3.36 mg) in Subjects With Edematous Fibrosclerotic Panniculopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Endo Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Endo Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and Pharmacokinetics (PK) of a single 3.36-mg dose of&#xD;
      Collagenase Clostridium Histolyticum (CCH) in 4 quadrants concurrently, in subjects with&#xD;
      Edematous fibrosclerotic panniculopathy (EFP).&#xD;
&#xD;
      This study will provide insight to the PK profile and safety of concurrent subcutaneous&#xD;
      injections of CCH 0.84 mg/quadrant into 4 quadrants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 18, 2018</start_date>
  <completion_date type="Actual">November 1, 2018</completion_date>
  <primary_completion_date type="Actual">November 1, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma AUX-I and AUX-II Concentrations</measure>
    <time_frame>Day 1 to Day 22</time_frame>
    <description>Determine if there is systemic exposure following a subcutaneous single dose of Collagenase clostridium histolyticum (CCH) (3.36 mg) as 12 injections per quadrant in 4 quadrants concurrently (0.84 mg per quadrant) in adult women with Edematous Fibrosclerotic Panniculopathy (EFP). There were no quantifiable levels of plasma AUX-I or AUX-II observed at any collection time point following subcutaneous injection of EN3835. As a result, no pharmacokinetic (PK) parameters were calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigator CR-PCSS Rating</measure>
    <time_frame>Day 1 to Day 22</time_frame>
    <description>Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) scores for each quadrant are based on the investigator's CR-PCSS evaluation done at the Screening visit (Baseline) and at End of Study (Day 22). CR-PCSS is a 5-level scale ranging from &quot;0&quot; (None) to &quot;4&quot; (Severe). Negative change reflects an improvement in cellulite severity; positive change reflects a worsening in cellulite severity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigator CR-PCSS Change From Baseline</measure>
    <time_frame>Day 1 to Day 22</time_frame>
    <description>Change from Baseline (Day 22 - Baseline). Baseline Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) scores for each quadrant are based on the investigator's CR-PCSS evaluation done at the Screening visit. CR-PCSS is a 5-level scale ranging from &quot;0&quot; (None) to &quot;4&quot; (Severe). Negative change reflects an improvement in cellulite severity; positive change reflects a worsening in cellulite severity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigator CR-PCSS Responder Analysis at End of Study</measure>
    <time_frame>Day 22</time_frame>
    <description>Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) scores for each quadrant are based on the investigator's CR-PCSS evaluation at the end of study. CR-PCSS is a 5-level scale ranging from &quot;0&quot; (None) to &quot;4&quot; (Severe). A 2-point responder is a participant with a reduction of cellulite severity by at least 2 severity levels from baseline to end of study (i.e., change from baseline CR-PCSS rating of -2, -3, or -4). A 1-point responder is a participant with a reduction of cellulite severity by at least 1 severity level from baseline to end of study (i.e., change from baseline CR-PCSS rating of -1, -2, -3, or -4).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Edematous Fibrosclerotic Panniculopathy</condition>
  <arm_group>
    <arm_group_label>CCH (Collagenase clostridium histolyticum)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CCH (collagenase clostridium histolyticum)</intervention_name>
    <description>A single dose of 3.36 mg of CCH will be administered as subcutaneous injections (CCH 0.84 mg) per quadrant concurrently in 4 quadrants. A quadrant is defined as one of the following: left buttock, right buttock, left posterolateral thigh, or right posterolateral thigh.</description>
    <arm_group_label>CCH (Collagenase clostridium histolyticum)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  No subject will be dosed until all eligibility criteria have been satisfied. In order&#xD;
             to be eligible to participate in the study, subjects must meet the following criteria:&#xD;
&#xD;
               1. Be a female ≥18 years of age.&#xD;
&#xD;
               2. Have evidence of cellulite within 4 quadrants (a quadrant is defined as a left&#xD;
                  buttock, right buttock, left posterolateral thigh or right posterolateral thigh)&#xD;
                  as assessed by the Investigator using the Clinician-Reported Photonumeric&#xD;
                  Cellulite Severity Scale (CR-PCSS) at the Screening visit; has a score of 2&#xD;
                  (mild), 3 (moderate) or 4 (severe) as reported by the Investigator (CR-PCSS) in 4&#xD;
                  quadrants at the Screening visit.&#xD;
&#xD;
               3. Have a body mass index (BMI) between 20.0 and 35.0 kg/m^2, and intends to&#xD;
                  maintain stable body weight throughout the duration of the study (a variation of&#xD;
                  ≤10% from baseline body weight is permitted).&#xD;
&#xD;
               4. Be willing to apply sunscreen to the dosing quadrants before each exposure to the&#xD;
                  sun while participating in the study (ie, screening through end of study).&#xD;
&#xD;
               5. Be judged to be in good health, based upon the results of a medical history,&#xD;
                  physical examination, and laboratory profile at screening.&#xD;
&#xD;
               6. Have a negative pregnancy test at the Screening visit and on Day -1 at admission&#xD;
                  (before injection of study drug); and be using an effective contraception method&#xD;
                  (e.g., abstinence, intrauterine device [IUD], hormonal [estrogen/progestin]&#xD;
                  contraceptives, or double barrier control) for at least 1 menstrual cycle prior&#xD;
                  to study enrollment and for the duration of the study; or be menopausal defined&#xD;
                  as 12 months of amenorrhea in the absence of other biological or physiological&#xD;
                  causes, as determined by the Investigator; or post-menopausal for at least 1&#xD;
                  year; or be surgically sterile (i.e., hysterectomy, bilateral oophorectomy, tubal&#xD;
                  ligation).&#xD;
&#xD;
               7. Be willing and able to cooperate with the requirements of the study.&#xD;
&#xD;
               8. Voluntarily sign and date an informed consent form approved by the Institutional&#xD;
                  Review Board/Independent Ethics Committee/Human Research Ethics Committee&#xD;
                  (IRB/IEC/HREC).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A subject will be excluded from study participation if she:&#xD;
&#xD;
               1. Has any of the following systemic conditions:&#xD;
&#xD;
                    1. Coagulation disorder&#xD;
&#xD;
                    2. Evidence or history of malignancy (other than excised basal-cell carcinoma)&#xD;
                       unless there has been no recurrence in at least 5 years&#xD;
&#xD;
                    3. History of keloidal scarring or abnormal wound healing&#xD;
&#xD;
                    4. Concurrent diseases or conditions that might interfere with the conduct of&#xD;
                       the study, confound the interpretation of the study results, or endanger the&#xD;
                       subject's well-being. Any questions about concurrent diseases should be&#xD;
                       discussed with the Medical Monitor.&#xD;
&#xD;
                    5. Evidence of clinically significant abnormalities on physical examination,&#xD;
                       vital signs, electrocardiogram (ECG), or clinical laboratory values.&#xD;
&#xD;
               2. Has any of the following local conditions in the areas to be treated:&#xD;
&#xD;
                    1. History of lower extremity thrombosis or post-thrombosis syndrome&#xD;
&#xD;
                    2. Vascular disorder (e.g., varicose veins) in areas to be treated&#xD;
&#xD;
                    3. Inflammation or active infection&#xD;
&#xD;
                    4. Active cutaneous alteration including rash, eczema, psoriasis, or skin&#xD;
                       cancer&#xD;
&#xD;
                    5. Has a tattoo located within 2 cm of the site of injection&#xD;
&#xD;
               3. Requires the following concomitant medications before or during participation in&#xD;
                  the trial:&#xD;
&#xD;
                  a. Anticoagulant or antiplatelet medication or has received anticoagulant or&#xD;
                  antiplatelet medication (except for ≤150 mg aspirin daily) within 7 days before&#xD;
                  injection of study drug&#xD;
&#xD;
               4. Has a positive test on a urine drug screen for drugs of abuse&#xD;
&#xD;
               5. Has a history of drug or alcohol abuse&#xD;
&#xD;
               6. Has used any of the following for the treatment of EFP on the legs or buttock&#xD;
                  within the timelines identified below or intends to use any of the following at&#xD;
                  any time during the course of the study:&#xD;
&#xD;
                    1. Liposuction within the treatment quadrants during the 12-month period before&#xD;
                       injection of study drug&#xD;
&#xD;
                    2. Injections (e.g., mesotherapy); radiofrequency device treatments; laser&#xD;
                       treatment; or surgery (including subcision and/or powered subcision) within&#xD;
                       the treatment quadrants during the 12-month period before injection of study&#xD;
                       drug&#xD;
&#xD;
                    3. Endermologie or similar treatments within the treatment quadrants during the&#xD;
                       6-month period before injection of study drug&#xD;
&#xD;
                    4. Massage therapy within the treatment quadrants during the 3-month period&#xD;
                       before injection of study drug&#xD;
&#xD;
                    5. Creams (e.g., Celluvera™, TriLastin®) to prevent or mitigate EFP within the&#xD;
                       treatment quadrants during the 2-week period before injection of study drug&#xD;
&#xD;
               7. Is presently nursing a baby or providing breast milk for a baby&#xD;
&#xD;
               8. Intends to become pregnant during the study&#xD;
&#xD;
               9. Intends to initiate an intensive sport or exercise program during the study&#xD;
&#xD;
              10. Intends to initiate a weight reduction program during the study&#xD;
&#xD;
              11. Has received an investigational drug or treatment within 30 days before injection&#xD;
                  of study drug&#xD;
&#xD;
              12. Has a known systemic allergy to collagenase or any other excipient of study drug&#xD;
&#xD;
              13. Has received any collagenase treatments at any time prior to treatment&#xD;
&#xD;
              14. Has been a subject in a previous cellulite clinical trial of CCH: AUX-CC-830,&#xD;
                  AUX-CC-831, EN3835-102, EN3835-104, EN3835-201, EN3835-202, EN3835-205,&#xD;
                  EN3835-302, EN3835-303, EN3835-304, and/or EN3835-209.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saji Vijayan, MD</last_name>
    <role>Study Director</role>
    <affiliation>Endo Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #1</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 15, 2018</study_first_submitted>
  <study_first_submitted_qc>September 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2018</study_first_posted>
  <results_first_submitted>August 5, 2020</results_first_submitted>
  <results_first_submitted_qc>September 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 6, 2020</results_first_posted>
  <last_update_submitted>September 14, 2020</last_update_submitted>
  <last_update_submitted_qc>September 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cellulite</keyword>
  <keyword>Edematous Fibrosclerotic Panniculopathy</keyword>
  <keyword>EFP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 7, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT03675685/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 27, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT03675685/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CCH (Collagenase Clostridium Histolyticum)</title>
          <description>CCH (collagenase clostridium histolyticum): A single dose of 3.36 mg of CCH will be administered as subcutaneous injections (CCH 0.84 mg) per quadrant concurrently in 4 quadrants. A quadrant is defined as one of the following: left buttock, right buttock, left posterolateral thigh, or right posterolateral thigh.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CCH (Collagenase Clostridium Histolyticum)</title>
          <description>CCH (collagenase clostridium histolyticum): A single dose of 3.36 mg of CCH will be administered as subcutaneous injections (CCH 0.84 mg) per quadrant concurrently in 4 quadrants. A quadrant is defined as one of the following: left buttock, right buttock, left posterolateral thigh, or right posterolateral thigh.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.3" spread="10.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>(kg/m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.94" spread="3.574"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Skin Category (Fitzpatrick Scale)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>I (Pale White)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>II (Fair)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>III (Darker White)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>IV (Light Brown)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>V (Brown)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>VI (Dark Brown or Black)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Plasma AUX-I and AUX-II Concentrations</title>
        <description>Determine if there is systemic exposure following a subcutaneous single dose of Collagenase clostridium histolyticum (CCH) (3.36 mg) as 12 injections per quadrant in 4 quadrants concurrently (0.84 mg per quadrant) in adult women with Edematous Fibrosclerotic Panniculopathy (EFP). There were no quantifiable levels of plasma AUX-I or AUX-II observed at any collection time point following subcutaneous injection of EN3835. As a result, no pharmacokinetic (PK) parameters were calculated.</description>
        <time_frame>Day 1 to Day 22</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>CCH (Collagenase Clostridium Histolyticum)</title>
            <description>CCH (collagenase clostridium histolyticum): A single dose of 3.36 mg of CCH will be administered as subcutaneous injections (CCH 0.84 mg) per quadrant concurrently in 4 quadrants. A quadrant is defined as one of the following: left buttock, right buttock, left posterolateral thigh, or right posterolateral thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma AUX-I and AUX-II Concentrations</title>
          <description>Determine if there is systemic exposure following a subcutaneous single dose of Collagenase clostridium histolyticum (CCH) (3.36 mg) as 12 injections per quadrant in 4 quadrants concurrently (0.84 mg per quadrant) in adult women with Edematous Fibrosclerotic Panniculopathy (EFP). There were no quantifiable levels of plasma AUX-I or AUX-II observed at any collection time point following subcutaneous injection of EN3835. As a result, no pharmacokinetic (PK) parameters were calculated.</description>
          <population>Pharmacokinetic Population</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">There were no quantifiable levels of plasma AUX-I or AUX-II observed at any collection time point following subcutaneous injection of EN3835- As a result, no Pharmacokinetic (PK) parameters were calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Investigator CR-PCSS Rating</title>
        <description>Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) scores for each quadrant are based on the investigator's CR-PCSS evaluation done at the Screening visit (Baseline) and at End of Study (Day 22). CR-PCSS is a 5-level scale ranging from &quot;0&quot; (None) to &quot;4&quot; (Severe). Negative change reflects an improvement in cellulite severity; positive change reflects a worsening in cellulite severity.</description>
        <time_frame>Day 1 to Day 22</time_frame>
        <population>Cellulite Severity Population</population>
        <group_list>
          <group group_id="O1">
            <title>Left Buttock</title>
            <description>CCH 0.84 mg/Area, 3.36 mg Total</description>
          </group>
          <group group_id="O2">
            <title>Right Buttock</title>
            <description>CCH 0.84 mg/Area, 3.36 mg Total</description>
          </group>
          <group group_id="O3">
            <title>Left Thigh</title>
            <description>CCH 0.84 mg/Area, 3.36 mg Total</description>
          </group>
          <group group_id="O4">
            <title>Right Thigh</title>
            <description>CCH 0.84 mg/Area, 3.36 mg Total</description>
          </group>
        </group_list>
        <measure>
          <title>Investigator CR-PCSS Rating</title>
          <description>Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) scores for each quadrant are based on the investigator's CR-PCSS evaluation done at the Screening visit (Baseline) and at End of Study (Day 22). CR-PCSS is a 5-level scale ranging from &quot;0&quot; (None) to &quot;4&quot; (Severe). Negative change reflects an improvement in cellulite severity; positive change reflects a worsening in cellulite severity.</description>
          <population>Cellulite Severity Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening (Baseline)</title>
              <category_list>
                <category>
                  <title>None (0)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Almost None (1)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild (2)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate (3)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe (4)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 (End of Study)</title>
              <category_list>
                <category>
                  <title>None (0)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Almost None (1)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild (2)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate (3)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe (4)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Investigator CR-PCSS Change From Baseline</title>
        <description>Change from Baseline (Day 22 - Baseline). Baseline Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) scores for each quadrant are based on the investigator's CR-PCSS evaluation done at the Screening visit. CR-PCSS is a 5-level scale ranging from &quot;0&quot; (None) to &quot;4&quot; (Severe). Negative change reflects an improvement in cellulite severity; positive change reflects a worsening in cellulite severity.</description>
        <time_frame>Day 1 to Day 22</time_frame>
        <population>Cellulite Severity Population</population>
        <group_list>
          <group group_id="O1">
            <title>Left Buttock</title>
            <description>CCH 0.84 mg/Area, 3.36 mg Total</description>
          </group>
          <group group_id="O2">
            <title>Right Buttock</title>
            <description>CCH 0.84 mg/Area, 3.36 mg Total</description>
          </group>
          <group group_id="O3">
            <title>Left Thigh</title>
            <description>CCH 0.84 mg/Area, 3.36 mg Total</description>
          </group>
          <group group_id="O4">
            <title>Right Thigh</title>
            <description>CCH 0.84 mg/Area, 3.36 mg Total</description>
          </group>
        </group_list>
        <measure>
          <title>Investigator CR-PCSS Change From Baseline</title>
          <description>Change from Baseline (Day 22 - Baseline). Baseline Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) scores for each quadrant are based on the investigator's CR-PCSS evaluation done at the Screening visit. CR-PCSS is a 5-level scale ranging from &quot;0&quot; (None) to &quot;4&quot; (Severe). Negative change reflects an improvement in cellulite severity; positive change reflects a worsening in cellulite severity.</description>
          <population>Cellulite Severity Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>-4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>-3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>-2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>-1</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+1</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Investigator CR-PCSS Responder Analysis at End of Study</title>
        <description>Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) scores for each quadrant are based on the investigator's CR-PCSS evaluation at the end of study. CR-PCSS is a 5-level scale ranging from &quot;0&quot; (None) to &quot;4&quot; (Severe). A 2-point responder is a participant with a reduction of cellulite severity by at least 2 severity levels from baseline to end of study (i.e., change from baseline CR-PCSS rating of -2, -3, or -4). A 1-point responder is a participant with a reduction of cellulite severity by at least 1 severity level from baseline to end of study (i.e., change from baseline CR-PCSS rating of -1, -2, -3, or -4).</description>
        <time_frame>Day 22</time_frame>
        <population>Cellulite Severity Population</population>
        <group_list>
          <group group_id="O1">
            <title>Left Buttock</title>
            <description>CCH 0.84 mg/Area, 3.36 mg Total</description>
          </group>
          <group group_id="O2">
            <title>Right Buttock</title>
            <description>CCH 0.84 mg/Area, 3.36 mg Total</description>
          </group>
          <group group_id="O3">
            <title>Left Thigh</title>
            <description>CCH 0.84 mg/Area, 3.36 mg Total</description>
          </group>
          <group group_id="O4">
            <title>Right Thigh</title>
            <description>CCH 0.84 mg/Area, 3.36 mg Total</description>
          </group>
        </group_list>
        <measure>
          <title>Investigator CR-PCSS Responder Analysis at End of Study</title>
          <description>Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) scores for each quadrant are based on the investigator's CR-PCSS evaluation at the end of study. CR-PCSS is a 5-level scale ranging from &quot;0&quot; (None) to &quot;4&quot; (Severe). A 2-point responder is a participant with a reduction of cellulite severity by at least 2 severity levels from baseline to end of study (i.e., change from baseline CR-PCSS rating of -2, -3, or -4). A 1-point responder is a participant with a reduction of cellulite severity by at least 1 severity level from baseline to end of study (i.e., change from baseline CR-PCSS rating of -1, -2, -3, or -4).</description>
          <population>Cellulite Severity Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2-point Responder</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-point Responder</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All (serious and nonserious) AEs, from Day 1 up to Day 22</time_frame>
      <desc>All (serious and nonserious) AEs, whether elicited or observed during study visits or spontaneously reported by the participant, including events that occurred from the time the participant signed the study-specific consent form until completion of or discharge from the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>CCH (Collagenase Clostridium Histolyticum)</title>
          <description>CCH (collagenase clostridium histolyticum): A single dose of 3.36 mg of CCH will be administered as subcutaneous injections (CCH 0.84 mg) per quadrant concurrently in 4 quadrants. A quadrant is defined as one of the following: left buttock, right buttock, left posterolateral thigh, or right posterolateral thigh.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Injection site oedema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Injection site nodule</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Injection site warmth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Drug withdrawal headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Saji Vijayan, MBBS</name_or_title>
      <organization>Endo Pharmaceuticals</organization>
      <phone>800-462-3636</phone>
      <email>ClinicalTrials@Endo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

